Sheila Maier, DO
Endocrinology, Diabetes & Metabolism · Denver, CONPI 1033599162
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations.
Across 108 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$497
- Lilly USA, LLC$326
- Boehringer Ingelheim$207
- GSK$195
- Abbott$156
- Novo Nordisk$146
- plus $860 from 16 others
What the payments were for
- Food & beverage$2,376100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 27 | $497 |
| Lilly USA, LLC | 14 | $326 |
| Boehringer Ingelheim | 8 | $207 |
| GSK | 9 | $195 |
| Abbott | 6 | $156 |
| Novo Nordisk | 6 | $146 |
| Fresenius Kabi USA, LLC | 5 | $125 |
| E.r. Squibb & Sons, L.L.C. | 5 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $106 |
| Medtronic(2 entities) | 5 | $89 |
| Tandem Diabetes Care, Inc. | 3 | $86 |
| Bayer | 3 | $56 |
| Dexcom, Inc. | 2 | $52 |
| Sandoz | 2 | $40 |
| Johnson & Johnson | 1 | $35 |
| AstraZeneca | 1 | $28 |
| Sequel Med Tech, LLC | 1 | $26 |
| Vertex | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| UCB, Inc. | 1 | $22 |
| Sanofi | 1 | $20 |
| Insulet Corporation | 1 | $14 |
How this compares
$2,387 in reported general payments places this provider in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 334 | $627,554 |
| TrulicityDulaglutide | 276 | $434,949 |
| JardianceEmpagliflozin | 271 | $404,750 |
| MounjaroTirzepatide | 262 | $317,528 |
| FarxigaDapagliflozin Propanediol | 81 | $87,589 |
| Tresiba Flextouch U-100Insulin Degludec | 121 | $84,979 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $73,764 |
| RybelsusSemaglutide | 44 | $73,614 |
| ForteoTeriparatide | 16 | $62,264 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $62,120 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 59 | $53,933 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $36,163 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 59 | $29,569 |
| TymlosAbaloparatide | 11 | $28,750 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 35 | $27,230 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Forteo, Humalog, Baqsimi | $326 | $838,436633 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $146 | $706,921396 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $207 | $444,964304 claims |
| AstraZenecaFarxiga | $28 | $87,58981 claims |
| Johnson & JohnsonInvokana | $35 | $6,68312 claims |
| Sanofi-aventis U.S. LLCAdmelog | $25 | $4,87211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Denver
- Daniel BessesenDenver$34K
- Michael LoughnerDenver$32K
- Leonard ZemelDenver$19K
- Alex GoldsmithDenver$12K
- Daniel CitronDenver$8K
- Sarah BullDenver$4K
- Leslie GamacheDenver$4K
- Claudia PanzerDenver$3K
- Karin HickeyDenver$2K
- Gregory LundDenver$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.